Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG Plus Rituximab in Highly-HLA Sensitized Patients Awaiting Kidney Transplantation
NCT01178216Phase 2Completed
- Start
- Sep 2013
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in end stage renal disease (ESRD). Primary endpoint: Number of Patients That Underwent Transplantation at 9 months. Started Sep 2013; status: completed.
02
Drugs
rituximab
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT01178216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01178216.